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Abstract
The dramatic increase in food allergy preva-
lence and severity globally is demanding
effective strategies. Food allergy derives from
a defect in immune tolerance mechanisms.
Immune tolerance is modulated by gut
microbiota composition and function, and gut
microbiota dysbiosis has been associated with
the development of food allergy. Selected pro-
biotic strains could act on immune tolerance
mechanisms. The mechanisms are multiple
and still not completely deﬁned. Increasing
evidence is providing useful information on
the choice of optimal bacterial species/strains,
dosage, and timing for intervention. The
increased knowledge on the crucial role played
by gut microbiota-derived metabolites, such as
butyrate, is also opening the way to a post-
biotic approach in the stimulation of immune
tolerance.
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1 Introduction
Food allergy (FA) is “an adverse health effect
arising from a speciﬁc immune response that
occurs reproducibly” according to the 2010
National Institute of Allergy and Infectious
Diseases, National Institutes of Health (NIAID/
NIH)-supported Guidelines for the Diagnosis and
Management of Food Allergy in the United States
(Boyce et al. 2010). It is one of the most common
allergic disorders in the pediatric age, and it has
been recognized as a global health problem that
affects millions of persons, particularly in devel-
oped countries. Studies have suggested that the
natural history of FA has changed during the last
two decades, with a dramatic rise in the preva-
lence, severity of clinical manifestations, and risk
of persistence into later ages, leading to an
increase in hospital admissions, medical visits,
treatments, and burden of care on families and
to an important economic impact, with signiﬁcant
direct costs for the families and healthcare system
(Skripak et al. 2007; McBride et al. 2012; Gupta
et al. 2013). In Europe, around seven million of
people suffer from challenge-proven FA. If this
prevalence is projected onto the world’s popula-
tion of seven billion, it translates into 63 million–
1.16 billion of potential food-allergic people, with
a greater incidence in children (5–8%) than in
adults (1–2%) (Fiocchi et al. 2010). Furthermore,
about 8% of people suffering from FA are
exposed to the risk of potentially life-threatening
allergic reaction resulting in death, mainly among
children aged 0–14 years. According to the most
recently available epidemiological data, time
trend analysis showed up to sevenfold increase
in hospital admissions for severe food-allergic
reactions in children in the UK, USA, Italy, and
Australia over the last 10 years (Berni Canani
et al. 2013; Turner et al. 2015; Mullins et al.
2015; Nocerino et al. 2015; Mullins et al. 2016).
Although more than 170 foods have been
identiﬁed as triggers of FA, there is a rather
short list of foods account for most of the more
serious disease burden: namely peanuts, tree nuts,
ﬁsh, shellﬁsh, egg, milk, wheat, soy, and seeds,
with national and geographical variations
concerning the most common FA (Boyce et al.
2010; Sicherer et al. 2010; Ben-Shoshan et al.
2010; Chafen et al. 2010; Osborne et al. 2011;
Gupta et al. 2011; National Academies of
Sciences 2016).
Food allergy derives from a breakdown of
immune tolerance. Current knowledge suggests
that the development of FA might be inﬂuenced
by genetics, environment, and genome-
environment interactions, leading to immune sys-
tem dysfunction, mediated at least in part by
epigenetic mechanisms (Berni Canani et al.
2015; Paparo et al. 2018). Many factors have
been postulated to contribute to the onset of
FA. Among the multiple immutable risk factors
that could inﬂuence FA onset, there are the male
sex, the race/ethnicity (increased risk among
Asian and black children compared with white
children), and genetics (familial associations,
HLA, and speciﬁc genes) (National Academies
of Sciences 2016; Sicherer et al. 2017; Allen and
Koplin 2016; du Toit et al. 2016; Hong et al.
2015; Gupta et al. 2016). In addition, there are
other risk factors that can be addressed to poten-
tially reduce/prevent FA, such as atopic disease
manifestations (comorbid atopic dermatitis),
increased hygiene, vitamin D insufﬁciency,
dietary fat (reduced consumption of omega-3-
polyunsaturated fatty acids), reduced
consumption of antioxidants, increased use of
antacids (that reduce digestion of allergens),
obesity, the timing and route of exposure to
foods (increased risk for delaying oral ingestion
of allergens with environmental exposure in the
absence of oral exposure leading to sensitization
and allergy), and in particular the inﬂuence of the
microbiome (Savage et al. 2018; Huang et al.
2017; Sicherer et al. 2010). There is mounting
evidence that the alterations of microbiota com-
position early in life play a key role in early host
immunological development and represent a
critical factor underlying FA (Prince et al.
2015). Fig. 1 summarizes the main possible
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contributing factors that have been ascribed to FA
development. Many subjects with FA will natu-
rally outgrow it over time; however, the natural
course highly depends on the causative allergen.
For example, cow’s milk allergy (CMA) usually
resolves in more than 50% of children by age
5–10 years, hen’s egg allergy approximately
resolves in 50% of children by age 5–10 years,
and 50% of children with wheat allergy outgrow
by age 7 years. Other FAs (peanut, tree nut, ﬁsh)
have low rates of resolution or are considered
persistent (Savage et al. 2016). There is no Food
and Drug Administration (FDA)-approved treat-
ment for FA, and the current standard of care is
the strict and careful dietary avoidance of the
offending food allergens with the risk of
nutritional deﬁciencies. In addition, the risks of
accidental ingestion are relatively common, and
the prompt treatment of symptoms with
antihistamines, glucocorticoids, or epinephrine
in case of systemic reactions is advocated. All
these factors contribute to anxiety and stress and
signiﬁcantly affect the quality of life of patients
and their families (Burks et al. 2018; Sicherer and
Sampson 2018; Heine 2018). However, in the
past 10 years, a signiﬁcant amount of emerging
therapies for FA have been addressed. These
therapeutic strategies are focused on reducing
levels of allergen-speciﬁc IgE, enhancing levels
of allergen-speciﬁc IgG or IgA, suppressing Th2
effector cells, or enhancing regulatory T cells
through a variety of allergen-speciﬁc and allergen
non-speciﬁc strategies (Berin 2014). The main
new therapeutic perspectives for the treatment of
FA include allergen-speciﬁc (oral, sublingual,
epicutaneous, subcutaneous immunotherapy and
heat treatment of food) and non-allergen-speciﬁc
therapies (humanized monoclonal antibodies,
anti-IgE and anti-IL5, probiotics). Allergen-
speciﬁc therapies are successful to variable
Fig. 1 Gut microbiota as a target of intervention against
allergy. Several environmental and dietary factors could
modulate the diet-microbiota-epigenetics axis inﬂuencing
the occurrence of food allergy. On the left side of the ﬁgure
are summarized the most relevant factors able to increase
the risk of food allergy (red arrows), whereas on the right
side of the ﬁgure are reported the most beneﬁcial factors
able to protect the baby against the occurrence of food
allergy (blue arrows)
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degrees in achieving desensitization, deﬁned as
increased threshold for reaction to food allergen,
with regular exposition to the allergen. On the
other hand, to date, none of these experimental
therapies have been shown to lead to permanent
tolerance or cure, deﬁned as the absence of
symptoms after ingestion of the food allergen ad
libitum even after prolonged periods of avoid-
ance, and safety remains a major concern (Burks
et al. 2018; Rachid et al. 2018). Recent data are
focused also on heat treatment of food, with the
modiﬁcations of allergen structure to reduce IgE
binding. The introduction of extensively heated
milk and egg protein into the diet of subjects with
milk and egg allergy who tolerate the baked form,
rather than strict avoidance, is becoming an alter-
native approach to induce a faster acquisition of
immune tolerance (about 10 times more likely to
outgrow allergy comparing to those who strictly
avoid allergen), with changes in immune
parameters (increase in IgG4 and decrease in
allergen-speciﬁc IgE) (Wood et al. 2013; Sicherer
et al. 2014). Heating to reduce allergenicity is not
applicable to antigens such as peanut, where high
heat increases allergenicity rather than reducing
it. In this case, allergens can be also modiﬁed
through digestion, which forms peptides that are
too short to cross-link IgE but maintain T cell
epitopes that would have the capacity to generate
T cell-mediated immunomodulation (Ramesh
et al. 2016). However, all these strategies present
several pitfalls and uncertainties: optimal dose,
frequency and duration, adverse events, potential
for onset of eosinophilic esophagitis, achieving of
desensitization but not immunological tolerance,
and long-term efﬁcacy. Thus, their precise role in
the management of FA has yet to be determined
(Rachid et al. 2018). Among the non-allergen-
speciﬁc therapies, the more promising approach
for FA treatment is the use of probiotics, deﬁned
as live microorganisms that when consumed in
adequate amounts as part of food or as oral
supplements confer a health beneﬁt on the host
(Hill et al. 2014). Probiotics actions are mainly
mediated via the innate immune system (toll-like
receptors), resulting in the promotion of T helper
1 differentiation, production of regulatory
cytokines (IL-10 and TGF-beta), and enhanced
intestinal IgA responses (Rautava et al. 2012).
The effects can vary widely, depending on the
probiotic strain, dose, timing, and food matrix
used (Heine 2018). This therapeutic strategy
represents attempt to deliberately modify the
microbiota and their metabolism, with the idea
that manipulating microbial communities to the
host’s advantages could treat FA (Ho and
Bunyavanich 2018). This review is focused on
the preclinical and clinical evidence on the role
of probiotics in preventing or treating FA.
2 Main Preclinical Evidence
on the Probiotics Efficacy
in Food Allergy
Immune tolerance is the most important therapeu-
tic target in FA. Immune tolerance is modulated
by the activity of a well-modulated network com-
posed by several immune and nonimmune
mechanisms. Gut microbiota and its metabolites
(mainly the short-chain fatty acid, butyrate) exert
a pivotal role in immune tolerance. Main preclin-
ical evidence on the probiotics activity against FA
are summarized in Table 1. Evidence support the
concept that probiotics could act at different level
on immune tolerance network in FA: modulating
gut microbiota composition and function
(increased production of butyrate (Berni Canani
et al. 2016) and interacting with enterocytes with
subsequent modulation of nonimmune (gut
permeability and mucus thickness) (Sudo et al.
1997; Sütas et al. 1996; Malin et al. 1997) and
immune tolerogenic mechanisms (stimulation of
sIgA and beta-defensins production) (Hardy et al.
2013) and modulation of cytokines response by
immune cells (Kim et al. 2008; Torii et al. 2007;
Maassen et al. 2000; Niers et al. 2005; Takahashi
et al. 2006a, b). In vitro stimulation of human
peripheral blood mononuclear cells (PBMCs)
with selected probiotic strains is a commonly
used experimental tool for the investigation of
the effect of these microorganisms on immune
cells. The incubation of PBMCs with lactic acid
bacteria (LAB) strains such as Lactobacillus
plantarum (L. plantarum) and Biﬁdobacterium
adolescentis (B. adolescentis) resulted in an
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increase in the production of the regulatory cyto-
kine IL-10 by monocytes and dendritic cells and
to an enhance of IFN-γ production by T cells
(Cross and Gill 2001; Karlsson et al. 2004,
Mohamadzadeh et al. 2005). The addition of
probiotics mixture (L. acidophilus W55,
L. casei W56, L. salivarius W57, L. lactis
W58, B. infantis W52, B. lactis W18, and
B. longum W51) to PBMCs from children with
FA resulted in increased T cell proliferation with
enhanced production of Th1 and regulatory
cytokines (Flinterman et al. 2007). An increase
in T and B cell proliferation and a reduction in
IgE production were also observed in PBMCs
from children with FA treated for 3 months with
the same probiotic mixture (Flinterman et al.
2007). Using a 3D co-culture model of intestinal
epithelial cells and PBMCs as an in vitro model
of the intestinal mucosal immune system,
Ghadimi et al. demonstrated that a commensal
probiotics B. breve and L. rhamnosus GG (LGG)
inhibit activation of inﬂammatory IL-23 and
IL-17 cytokines, thereby reducing histone acety-
lation and simultaneously enhancing DNA
Table 1 Main preclinical evidences on the probiotics role against food allergy
Biological effects Bacterial strains References
Intestinal barrier maturation Biﬁdobacterium lactis/biﬁdum Sudo et al. (1997)
Lactobacillus rhamnosus GG Sütas et al. (1996)
Malin et al. (1997)
Immune response modulation Th1/Th2 balance: Th1
production
Biﬁdobacterium lactis/biﬁdum Kim et al. (2008)
Lactobacillus acidophilus/
reuteri
Lactobacillus rhamnosus GG Torii et al. (2007)
Maassen et al. (2000)
Immune response modulation Th1/Th2 balance: Th2
suppression
Biﬁdobacterium biﬁdum/infantis/
longum
Niers et al. (2005)
Lactobacillus acidophilus/
reuteri
Lactobacillus rhamnosus GG Takahashi et al. (2006a,
b)
Kim et al. (2008)
Aitoro et al. (2017a, b)
Immune system regulation: regulatory T (Treg) cell
development
Biﬁdobacterium biﬁdum/infantis/
lactis
Niers et al. (2005)
Lactobacillus acidophilus/
reuteri/casei
Lactobacillus rhamnosus GG
Maassen et al. (2000)
Kim et al. (2008)
Smits et al. (2005)
Immune system regulation: tolerogenic dendritic cell
development
Biﬁdobacterium biﬁdum Niers et al. (2005)
Lactobacillus reuteri/casei
Lactobacillus rhamnosus GG Mohamadzadeh et al.
(2005)
Braat et al. (2004)
Smits et al. (2005)
Immunomodulation: suppression of IgE production Biﬁdobacterium biﬁdum/longum Kim et al. (2008)
Biﬁdobacterium lactis Bb-12
Lactobacillus acidophilus Takahashi et al.
(2006a, b)
Lactobacillus rhamnosus GG Borthakur et al. (2008)
Borchers et al. (2002)
Torii et al. (2007)
Epigenetic modulation of TH1/Th2 genes expression Biﬁdobacterium breve Ghadimi et al. (2012)
Lactobacillus rhamnosus GG
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methylation (Ghadimi et al. 2012). The limitation
of studying the effect of probiotics in vitro lies in
the extrapolation of the results to in vivo beneﬁts.
For that reason, another commonly used experi-
mental toll in this area is based on the use of animal
model of FA. Differential effects in relation to
molecular action of oral administration of three
LAB strains (B. coagulans 09.712 (Bc),
L. plantarum 08.923 (Lp), and B. infantis 11.322)
in alleviating Th2-driven intestinal inﬂammation
and other symptoms associated with food-induced
anaphylaxis were demonstrated in a murine model
induced by a major shrimp allergen, ST. In particu-
lar, oral supplementation with Bc and Lp signiﬁ-
cantly ameliorates anaphylaxis symptoms and
increases the population of CD4 + FoxP3+ T cells
in ST-sensitized mice through mTORC inhibition,
FoxP3 upregulation, and GATA-3 downregulation
(Linglin et al. 2017). Zang et al. investigated the
preventive and therapeutic effects of oral
C. butyricum on anaphylactic symptoms in FA
mice model induced by a β-lactoglobulin (BLG)
as allergen, a well-established model of CMA. The
authors observed that the oral treatment with
C. butyricum signiﬁcantly ameliorated anaphylaxis
symptoms and increased sIgA and CD4+ CD25+
FoxP3Treg cell in the spleen from BLG-sensitized
mice (Juan et al. 2017). Neonatal monocolonization
of germ-free mice by L. casei BL23 modulated the
allergic sensitization to cow’s milk proteins, devel-
oped higher IgG responses against caseins, and
elicited by L. casei that was able to hydrolyze
insoluble caseins into soluble immunogenic
peptides (Maiga et al. 2017). Using ovalbumin
(OVA)-sensitized murine model, it was
demonstrated that oral administration of
B. infantis ameliorated allergic symptoms, includ-
ing reducing OVA-speciﬁc IgE and IgG1 levels in
the serum and Th2 cytokines release in the spleen.
Moreover, gut microbiota analysis showed that the
probiotics-mediated protection was conferred by
upregulation of the relative abundance of
Coprococcus and Rikenella at genus level (Yang
et al. 2017). Similar results were obtained by others
that observed a decrease of concentrations of IgE,
IL-4, and IL-13 following administration of
B. infantis CGMCC313–2 in BLG-sensitized
mice (Meng-Yun et al. 2017). Oral administration
of VSL#3 to sensitized mice signiﬁcantly reduces
Th2 immune responses and protects against ana-
phylactic reactions induced by the allergen in a
mouse model of FA. Also, the incubation of
mouse spleen cells from sensitized mice with pro-
biotic mixture reduced allergen-stimulated IL-5 and
IL-13 production and increased of IFN-γ and IL-10
production (Schiavi et al. 2011). An immunoregu-
latory action by LGG has been demonstrated in a
murine model of CMA. LGG administration was
able to suppress of Th2 responses such as reduced
hypersensitivity scores and lowered serum cow’s
milk protein (CMP)-speciﬁc IgG1 while promoting
Th1 responses by causing elevated IFN-γ and
CMP-speciﬁc IgG2a levels (Thang et al. 2011).
Similar results have been reported by our group in
a BLG-sensitized mice model, in which we found
that the administration of extensively hydrolyzed
casein formula plus LGG elicited a signiﬁcant
reduction of allergic reaction and of IL-4, IL-5,
IL-13, and speciﬁc IgE production (Aitoro et al.
2017a, b). The studies of probiotic strain-speciﬁc
modulation on gut microbiota should be considered
as a key channel that could affect its in vivo action.
A strain-speciﬁc effect of different probiotic strains
could be associated with a different impact on gut
microbiota as demonstrated by Wang et al. (Wang
et al. 2015). Instead, oral application of any LAB
strains seemed to have no signiﬁcant effect on the
overall gut microbiota structure, but the amount of
speciﬁc species exerted notable changes (Ai et al.
2016).
Additional potential mechanisms by which
probiotics exert pro-tolerogenic effects in the gut
are related to the production of immunoregulatory
metabolites, which interact with the host immune
cells to promote non-responsiveness to innocuous
luminal antigens (Nowak-Wegrzyn and
Chatchatee 2017; Di Costanzo et al. 2016).
Probiotics ferment ﬁber to short-chain fatty acids
(SCFAs): butyrate, acetate, and propionate. Evi-
dence suggests that SCFAs, particularly butyrate,
contribute to mucosal homeostasis through the
induction of Tregs and the regulation of epithelial
barrier integrity (Berni Canani et al. 2015). Buty-
rate deﬁciency has been observed in allergic
patients (Sandin et al. 2009; Berni Canani et al.
2016). It is possible to hypothesize that different
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type of dysbiosis could lead to similar effects in
term of SCFAs or of other microbiota-derived
metabolites production that could facilitate the
occurrence of allergy. Clostridia species belonging
to cluster IV and XIVa are the prominent source of
SCFAs in the colon. Bacteria-produced SCFAs
have been implicated in the regulation of both the
proportions and functional capabilities of Tregs in
the colon (Arpaia and Campbell 2013; Smith and
Howitt 2013), which, in some studies, has been
speciﬁcally attributed to butyrate production by
spore-forming Clostridiales (Furusawa and Obata
2013). SCFAs bind metabolite-sensing G-protein-
coupled receptors (GPCRs) GPR43, GPR 109A,
and GPR41 with varying afﬁnities. These GPCRs
are expressed on epithelial cells and immune cells.
SCFAs activate GPCRs that stimulate colonic den-
dritic cells and macrophages to secrete IL-10 and
promote development of Tregs in the mesenteric
lymph nodes. Tregs are a source of tolerogenic
cytokines, such as IL-10 and TGF-β that inhibit
allergic and inﬂammatory responses. Tan et al.
showed that dietary ﬁber/SCFAs together with
vitamin A and a healthy gut microbiota maintain
a tolerogenic mucosal environment and protect
against the development of FA. This is achieved
principally through enhancement of the
tolerogenic CD103+ dendritic cells function, lead-
ing to increased Tregs differentiation. In addition,
mice lacking GPR43 or GPR109A receptors for
SCFAs showed exacerbated FA and fewer CD103
+ dendritic cells (Tan et al. 2016). Data from our
laboratory showed that oral butyrate treatment
induces a dramatic inhibition of acute allergic
skin response, anaphylactic symptom score, body
temperature decrease, intestinal permeability
increase, and anti-BLG-IgE, IL-4, and IL-10 pro-
duction in a murine model of CMA, suggesting a
protective role of butyrate against FA (Aitoro et al.
2017a, b). The mechanisms of action of butyrate
are multiple; many of these involve an epigenetic
regulation of gene expression through the inhibi-
tion of histone deacetylase (HDAC). The inhibi-
tion of HDAC 9 and 6 increases FoxP3 gene
expression, as well as the production and suppres-
sive function of Tregs (Tao and de Zoeten 2007).
We evaluated the direct effects of butyrate on
peripheral blood mononuclear cells (PBMCs)
from children affected by challenge-proven
IgE-mediated CMA. PBMCs were stimulated
with BLG in the presence or absence of butyrate.
Preliminary results showed that butyrate stimulates
IL-10 and IFN-γ production and decreases DNA
methylation rate of these two cytokines. Same
effective butyrate dose induces FoxP3 promoter
region demethylation and HDAC6/HDAC9
expression downregulation. The identiﬁcation of
bacterial metabolites, that affect positively the
immune tolerance network, may be an interesting
strategy against FA using a post-biotic approach.
3 Main Clinical Evidences
on the Probiotics Efficacy
in Food Allergy
The increasing evidence on the importance of the
composition of the gut microbiota in the patho-
genesis of FA supports clinical research on the
potential role of the probiotics against these
conditions. In this light, several studies have
revealed the efﬁcacy of selected probiotic strains
against FA. The effect appears strain speciﬁc and
more evident in the pediatric age. Thus, in a
randomized double-blind placebo-controlled
trial, it has been demonstrated that the adminis-
tration of L. casei CRL431 and B. lactis BB12
added to hypoallergenic formula for 12 months
did not affect the acquisition of immune tolerance
to cow’s milk proteins in infants with CMA (Hol
et al. 2008). Whereas using a similar study
design, we have demonstrated that the addition
of the probiotic LGG to the extensively
hydrolyzed casein formula (EHCF) is able to
accelerate immune tolerance acquisition in infants
with CMA. Infants (aged 1–12 months), consec-
utively referred for suspected CMA (IgE- or
non-IgE-mediated) but still receiving cow’s milk
proteins, were invited to participate in the study.
Subjects were randomly allocated to one of the
two groups of dietary interventions: control
group, received an EHCF, and active group,
received an EHCF containing LGG (at least
1.4  107 CFU/100 mL). After 12 months, the
double-blind placebo-controlled food challenge
was negative in 15 of 28 control infants (53.6%)
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and in 22 of 27 infants receiving EHCF with LGG
(81.5%, p¼ 0.027) (Berni Canani et al. 2012a, b).
The results were conﬁrmed in a subsequent trial,
when the effect of ﬁve different dietary strategies
was investigated: EHCF, EHCF + LGG, partially
hydrolyzed rice formula, soy formula, or amino
acid-based formula, in children affected by IgE-
or non-IgE-mediated CMA. After the treatment
period of 12 months, the proportion of children
acquiring tolerance to cow’s milk proteins was
signiﬁcantly higher in the group receiving EHCF
+ LGG (78.9%) than in other groups (Berni
Canani et al. 2013). At the 3-year follow-up of
another pediatric cohort, a further conﬁrmation of
a greater rate of resolution of IgE-mediated CMA
as well as a lower incidence of other atopic
manifestations was described after treatment
with EHCF+LGG (Berni Canani et al. 2017).
These effects could derive at least in part by a
modulation elicited by selected LGG components
on immune functions through different pathways
including enterocytes, monocytes, mast cells,
DCs, and Tregs (Berni Canani et al. 2013; Pan
et al. 2010; Ghadimi et al. 2008; Donato et al.
2010; Mileti et al. 2009) and by an expansion of
butyrate-producing gut microbiota (Berni Canani
et al. 2016). Accordingly, studies in infants with
eczema and/or CMA who received EHCF
supplemented with LGG showed beneﬁts in
decreasing gastrointestinal symptoms and inﬂam-
mation (Isolauri et al. 2000; Baldassarre et al.
2010). Ingestion of LGG for periods ranging
from 4 to 12 weeks has been associated with
signiﬁcant decreases in atopic dermatitis score
compared with placebo in some small studies,
but not in several more recent and larger trials
(Wu et al. 2017). Others were unable to detect
signiﬁcant differences in the group overall but
found the LGG-associated improvements to be
signiﬁcant in subgroups of children with
IgE-associated disease (Viljanen et al. 2005).
The combination of four probiotics (LGG,
L. rhamnosus LC705, B. breve Bb99, and
Propionibacterium freudenreichii ssp. shermanii)
given in association with a prebiotic (galactooli-
gosaccharides) reduced the incidence of eczema
and atopic eczema and tended to reduce
IgE-associated diseases overall in a primary
prevention trial (Kukkonen et al. 2007). The
same combination without prebiotic did not
have a signiﬁcant effect (Viljanen et al. 2005).
The addition of prebiotic may have been the
decisive difference, although clear evidence of
its biﬁdogenic effect is still lacking.
Probiotics have been also proposed to rein-
force the effectiveness of immunotherapy
(Rachid and Keet 2018). Oral food immunother-
apy (OIT) is currently the most investigated
approach for persistent FA, and it is based on
the concept that repeated oral/intestinal exposures
to antigens normally lead to tolerance. Tang et al.
performed a randomized double-blind placebo-
controlled trial with the probiotic L. rhamnosus
CGMCC 1.3724 and peanut OIT (PPOIT) in
62 children with peanut allergy. Subjects received
a ﬁxed dose of probiotic (or placebo) together
with peanut OIT (or placebo) once daily for a
total of 18 months. Sustained unresponsiveness
(SU), determined by DBPCFC conducted
2–5 weeks after discontinuation of treatment,
was achieved in 82.1% of patients receiving
PPOIT compared with 3.6% of those receiving
placebo, the highest rate of SU reported for any
food immunotherapy treatment evaluated in a
randomized controlled study to date. PPOIT also
induced high rates of desensitization (90%) and
was associated with reduced peanut skin test reac-
tivity, decreased peanut-speciﬁc IgE, and
increased peanut-speciﬁc IgG4 levels. PPOIT
was well tolerated with no participants
withdrawing because of adverse reactions (six
participants withdrew for reasons unrelated to
PPOIT treatment); this is in stark contrast to
OIT whereby 10–30% of participants withdraw
because of adverse reactions. At approximately
4 years after the study ended, 67% were still
consuming peanut, and only 58% of the
12 participants who stopped peanut ingestion for
8 weeks demonstrated sustained unresponsive-
ness. Importantly, no OIT control group was
evaluated to determine if the probiotic itself had
any effect on SU (Tang et al. 2015). Further
studies comparing peanut OIT with probiotic
with peanut OIT with placebo will be required
to evaluate this further.
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4 Conclusions
Gut microbiota dysbiosis early in life could be a
critical factor affecting the development of
FA. Studies are promising, but more data are
needed to support a wide use of probiotics against
FA. Currently there are no positive
recommendations from any scientiﬁc society to
use speciﬁc probiotic strains for the prevention or
treatment of FA. But, understanding how
probiotics could inﬂuence gut bacteria
communities and the immune system is opening
the way to novel preventive and therapeutic
strategies for FA. At this point, we need:
• More data on gut microbiota dysbiosis in chil-
dren with allergic diseases.
• More data to determine whether changes in gut
microbiota can occur as a result of probiotic
therapy
• More data on the mechanisms of action
elicited by selected probiotics against food
allergy.
• Further studies to deﬁne optimal dose, timing,
and combination of agents, as well as the opti-
mal patient populations to achieve beneﬁcial
effects
• Replication of the promising results in collab-
orative well-designed multicenter studies with
multidisciplinary expertise in pediatrics, gas-
troenterology, immunology, allergy, and
microbiology
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